Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 120 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Selective Serotonin Uptake Inhibitors ("SSRI") Clear all

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo oral tablet; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 60 Years to 90 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteer
Interventions: RO4917523, escitalopram, methylphenidate, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Acute Stroke, Visual Field Loss
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Bogachan Sahin; Other
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Major Depressive Disorder (MDD)
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Chino, California + 25 more

Conditions: Bipolar Disorder, Major Depressive Disorder, Psychosis
Interventions: Lurasidone, FDA Approved antidepressant treatment; Drug
Lead sponsor: George West Mental Health Foundation d/b/a Skyland Trail; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Alzheimer Disease
Interventions: Escitalopram Pill, Venlafaxine Pill, Placebo Oral Tablet; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 60 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Borderline Personality Disorder
Interventions: Fluoxetine, Dialectical Behavior Therapy, Supportive psychotherapy; Drug · Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Generalized Anxiety Disorder, Panic Disorder
Interventions: Niravam, SSRI/SNRI; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Major Depressive Disorder
Interventions: LY2216684, Placebo, SSRI; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,416 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 22
States / cities: Irvine, California • La Habra, California • Redlands, California + 19 more

Conditions: Ejaculation
Interventions: Treatment sequence 2, Treatment sequence 1; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Anniston, Alabama • Tempe, Arizona • Costa Mesa, California + 3 more

Conditions: Anxiety Disorder of Adolescence
Interventions: Sertraline, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 16 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Panic Disorder
Interventions: Paroxetine, Clozapine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Obsessive-Compulsive Disorder
Interventions: selective serotonin reuptake inhibitor; Drug
Lead sponsor: University of Sao Paulo; Other
Eligibility: 18 Years to 50 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Aticaprant; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 871 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 87
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 70 more

Conditions: Major Depressive Disorder
Interventions: Creatine, Placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 12 Years to 21 Years · Female only
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Stress Disorders, Post-Traumatic, Alcohol Abuse, Substance-Related Disorders
Interventions: Seeking Safety, Sertraline, Pill placebo; Behavioral · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression, Asthma
Interventions: High severity group: Escitalopram, High severity group: Placebo, Low severity group: Escitalopram, Low severity group: Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Depressive Disorder
Interventions: Interpersonal Psychotherapy for Depressed Adolescents, Selective Serotonin Reuptake Inhibitor, Usual Care; Behavioral · Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 18 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Placebo; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Major Depressive Disorder (MDD)
Interventions: Vilazodone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Standard Clinical Care with an SSRI; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 60 Years
Enrollment: 228 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder, Irritability
Interventions: Brexpiprazole; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 15
States / cities: Tucson, Arizona • Glendale, California • Oakland, California + 12 more

Conditions: Major Depressive Disorder, Depression
Interventions: TC-5214, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 79
States / cities: Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more

Conditions: Pulmonary Disease, Chronic Obstructive, Major Depression
Interventions: Treatment Adherence Intervention, Enhanced Care; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 50 Years to 95 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: West Haverstraw, New York • White Plains, New York

Search by objective public record fields.

Mechanisms of Antidepressant Non-Response in Late-Life Depression

A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers

Fluoxetine for Visual Recovery After Ischemic Stroke

A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment

Sleep Quality, Cognitive Performance, and Computerized Cognitive Training

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder

Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic Disorder

A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder

A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

Predicting Treatment Response in Patients With OCD

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)

Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

Combined Treatment for Alcohol-Dependent Individuals With PTSD

Antidepressant Treatment at an Inner City Asthma Clinic

An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression

Contact: Developing New Clinical Management Strategies

Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone

Cellular Aging and Neurobiology of Depression Study

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

Treatment of Depressed Chronic Obstructive Pulmonary Disease Patients